Medical Press Release

Biomotum SPARK Robotic Exoskeleton Now Available to Investigators for Clinical Trials

Biomotum SPARK Robotic Exoskeleton Now Available to Investigators for Clinical Trials

After five years of research and development, Biomotum is ready to transition to a commercialization stage for its first product, the Biomotum SPARK robotic exoskeleton. The Biomotum SPARK is an active ankle exoskeleton for walking assistance. The company has its roots in helping children and young adults with cerebral palsy. In order to facilitate the commercialization and visibility for research partnerships of the Biomotum SPARK, the company has launched a new website and brand identity.

Biomotum SPARK pediatric medical exoskeleton 2021The SPARK Research System is now available to clinical and biomechanical investigators as a research tool to carry out clinical trials. “We’re excited to provide our untethered, go-anywhere system to researchers conducting basic human mobility studies as well as those exploring more translational clinical questions,” said Dr. Zach Lerner, the CTO, and Co-Founder of Biomotum, adding that “The lightweight, ease of use, and broad utility of the SPARK make it a great tool for a wide range of applications when studying human mobility.”

“We continue to seek partners who can help fulfill our mission of optimizing human mobility by providing intelligent and intuitive wearable systems to individuals with CP, stroke, and other conditions that impair neuromotor performance and mobility,” said CEO, Ray Browning. “As we take further steps toward becoming commercially available, we’re excited to launch our new brand identity and online presence, better representing the customers we serve,” said Browning.

The Biomotum SPARK Robotic Exoskeleton is an untethered, overground mobility system that applies assistive and resistive forces at the ankle to help rehabilitate and restore mobility to individuals affected by conditions like cerebral palsy and stroke. It is currently an experimental device only for use in a clinical research setting and has not yet been cleared by the FDA.

The company partnered with Freethink to create a video outlining how earlier prototypes of the SPARK ankle exoskeleton can help children with cerebral palsy increase walking speed and efficiency. Since the launch of the video, the design of the SPARK has been refined and the scope of who it may serve has also been broadened. Biomotum was founded in Flagstaff, AZ in 2019, by Dr. Zach Lerner, Dr. Ray Browning, and Joe Lerner.

Biomotum’s journey in commercializing the SPARK could facilitate raising more attention for pediatric exoskeletons.


Biomotum Launches New Website and Brand Identity to Support Robotic Exoskeleton Commercialization and Research Partnerships, Biomotum, Inc. Sept. 8th, 2021,

Biomotum Freethink, YouTube

1 Comment

Click here to post a comment

  • I’ve been following the keeogo/btemia system in Canada, now approved for stroke patients in the US. Your product looks similar. I have Inclusion Body Myositis with progressive weakness and difficulty walking. In Canada this assistive device and training is available to people with my diagnosis. I would like more information about your product and training. I am willing to volunteer with research at my own expense if I can be of use.

Upcoming Events

Read the latest issue of the Exoskeleton Report Magazine:

Exoskeleton Report Digital Magazine Feb 2024 Featured Image square